Search results for " Hormone-Dependent"

showing 10 items of 10 documents

The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma

2016

The prognostic value of sentinel lymph node micrometastases in invasive breast cancer patients is still widely debated. Even if, in the absence of unequivocal guidelines, the axillary lynphadenectomy is not still performed in the routine clinical care of these patients.We have retrospectively analyzed 746 patients with operable invasive breast cancer and clinically negative axillary lymph nodes. These patients underwent conservative surgery or total mastectomy with sentinel lymph node biopsy. Patients with micrometastases in the sentinel lymph node treated with axillary dissection has been checked and the involvement of the remaining lymph nodes analyzed. Patients with micrometastases in th…

AdultNeoplasms Hormone-DependentBiopsy Fine-NeedleBreast carcinomaBreast NeoplasmsHumansRadionuclide ImagingTechnetium Tc 99m Aggregated AlbuminMastectomyAgedRetrospective StudiesAged 80 and overSentinel Lymph Node BiopsyCarcinoma Ductal BreastMicrometaseMiddle AgedPrognosisCombined Modality TherapyCarcinoma LobularNeoplasm MicrometastasisLymphatic MetastasisBreast carcinoma; Micrometases; Sentinel lymph node; SurgeryAxillaLymph Node ExcisionFemaleSurgeryNeoplasm Recurrence LocalRadiopharmaceuticalsSentinel lymph node
researchProduct

Erratum: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and >…

AdultOncologyCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAntineoplastic Agents Hormonalmedicine.medical_treatmentAdministration OralPhases of clinical researchAnastrozoleBreast NeoplasmsAnastrozoleMetastasischemistry.chemical_compoundbreast cancerBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical StudiesHumansMedicineAgedGynecologybusiness.industrysequential hormonal therapyCancerMiddle AgedTriazolesmedicine.diseaseMetastatic breast cancerAndrostadienesOncologychemistryChemotherapy AdjuvantHormonal therapyFemaleHormone therapyCorrigendumbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Nitrosoureas Modes of Action and Perspectives in the Use of Hormone Receptor Affine Carrier Molecules

1989

Mechanisms of DNA adduct formation by antineoplastic 2-chloroethyl-N-nitrosoureas (CNUs) and of DNA damage induced by these compounds are discussed. CNUs are alkylating agents that form DNA-DNA cross-links as well as 2-chloroethylated and 2-hydroxyethylated adducts, the N-7-position of guanine being the predominantly alkylated site. A close correlation exists between the potential of a given compound to induce DNA-DNA cross-links and its antineoplastic effectiveness. However, levels of DNA-DNA cross-linking in bone marrow and extent of myelosuppression as measured in rodents are also closely correlated. The design of new cross-linking analogues capable of directing the antineoplastically re…

MaleNeoplasms Hormone-DependentDNA damageGuaninemedicine.medical_treatmentAntineoplastic AgentsReceptors Cell SurfaceNitrosourea CompoundsAdductStructure-Activity Relationshipchemistry.chemical_compoundBone MarrowmedicineAnimalsHumansRadiology Nuclear Medicine and imagingDrug Carriersbusiness.industryMammary Neoplasms ExperimentalProstatic NeoplasmsEstrogensHematologyGeneral MedicineSteroid hormoneOncologyMechanism of actionBiochemistrychemistryHormone receptormedicine.symptombusinessDNAHormoneActa Oncologica
researchProduct

Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Ef…

2021

Objective Eribulin mesylate (EM) is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin. EM has been reported to be active in metastatic breast cancer. In this paper, we report efficacy and safety of data of EM in a retrospective, real-world series of patients with poor prognosis, hormone-refractory, or triple-negative metastatic breast cancer. Materials and methods The analysis was carried out at 4 interrelated oncology centers. EM was delivered at the dose of 1.4 mg/m2 in 100 mL of normal saline over 2 to 5 minutes on days 1 and 8 every 21 days. EM was continued until disease progression or unacceptable toxicity. Side effects were reported every cycle …

Eribulin MesylateOncologyAdultCancer Researchmedicine.medical_specialtyNeoplasms Hormone-Dependenteribulin mesylateSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast Neoplasmstriple negative03 medical and health sciences0302 clinical medicineStable DiseaseBreast cancerbreast cancerInternal medicineAntineoplastic Combined Chemotherapy Protocolshormonal refractorymedicineHumans030212 general & internal medicineFuransSalineTriple-negative breast cancerAgedRetrospective StudiesChemotherapybusiness.industryKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerSettore MED/18 - Chirurgia GeneraleTreatment OutcomeOncology030220 oncology & carcinogenesisToxicityFemalebusiness
researchProduct

Chronic exposure to a GSM-like signal (mobile phone) does not stimulate the development of DMBA-induced mammary tumors in rats: results of three cons…

2002

Certain epidemiological and experimental studies raised concerns about the safety of radiofrequency (RF) electromagnetic fields because of a possible increased risk of leukemia and lymphoma. In this study, an RF field used in mobile telecommunication was tested using 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in female Sprague-Dawley rats as a model for human breast cancer. Three experiments were carried out under strictly standardized conditions and were started on the same day of three consecutive years. The field consisted of a GSM-like signal (900 MHz pulsed at 217 Hz, pulse width 577 micros) of relatively low power flux density (100 microW/cm(2) +/- 3 dB) and was appl…

Chronic exposuremedicine.medical_specialtyNeoplasms Hormone-DependentNeoplasms Radiation-InducedTime FactorsRadio Waves910-Dimethyl-12-benzanthraceneBiophysicsDMBASignalModels BiologicalRf fieldRats Sprague-DawleyMedicineAnimalsRadiology Nuclear Medicine and imagingLife TablesRadiationbusiness.industryCancerMammary Neoplasms ExperimentalDose-Response Relationship RadiationEstrogensEnvironmental Exposuremedicine.diseaseSurgeryRatsTelephoneIncreased riskModels AnimalCarcinogensFemalePower fluxSafetyNuclear medicinebusinessHuman breastRadiation research
researchProduct

Multiple Estrogen Function in Human Prostate Cancer Cells

1996

MalePCA3Oncologymedicine.medical_specialtyNeoplasms Hormone-DependentCell divisionmedicine.drug_classGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceHeat shock proteinInternal medicineTumor Cells CulturedAnimalsHumansMedicineHeat-Shock Proteinsbusiness.industryCadherinGeneral NeuroscienceProstatic NeoplasmsCancerEstrogensProstate-Specific AntigenCadherinsmedicine.diseaseRatsProstate-specific antigenReceptors EstrogenEstrogenCancer cellAndrogensbusinessCell DivisionAnnals of the New York Academy of Sciences
researchProduct

Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma

2012

Oral metronomic chemotherapy is a therapeutic option which is particularly attractive due to its ease of administration and low toxic burden. Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens.A retrospective analysis of 61 patients with advanced breast carcinoma was carried out with the aim of reporting activity in terms of response rate, control of tumor-related symptoms, outcome, and toxicity. All patients had hormonal therapy-resistant metastatic disease and had previously received two lines of chemotherapy. The first cohort of 22 patients received oral cyclophosphamide …

AdultAged 80 and overAntineoplastic Combined Chemotherapy ProtocolNeoplasms Hormone-DependentSettore MED/06 - Oncologia MedicaPalliative CareAdministration OralBreast NeoplasmsMiddle AgedDisease-Free SurvivalDrug Administration ScheduleCohort StudiesMethotrexateAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCohort StudieAntineoplastic Agents AlkylatingCyclophosphamideBreast NeoplasmAgedHumanNeoplasm StagingRetrospective Studies
researchProduct

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

2008

Abstract Purpose: Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. Experimental Design: Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression. Results: Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disea…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyNeoplasms Hormone-DependentEstrogen receptorBreast Neoplasmschemistry.chemical_compoundDrug Delivery SystemsBreast cancerAntigens NeoplasmInternal medicineProgesterone receptorBiomarkers TumormedicineHumansAgedAged 80 and overbusiness.industryHazard ratioCancerEpithelial cell adhesion moleculeMiddle AgedEpithelial Cell Adhesion MoleculePrognosismedicine.diseaseOncologychemistryHormone receptorLymphatic MetastasisFemaleBreast diseasebusinessCell Adhesion MoleculesClinical Cancer Research
researchProduct

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…

2014

Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…

OncologyAdultBridged-Ring CompoundsCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAxillary lymph nodesAnthracyclineDose-dense chemotherapyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAnthracyclinesAgedRetrospective StudiesAged 80 and overChemotherapyAnalysis of VarianceTaxanebusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTreatment OutcomeOncologyChemotherapy AdjuvantLymphatic MetastasisPractice Guidelines as TopicFemaleTaxoidsGuideline AdherencebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct